Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Lonza Group AG
  6. News
  7. Summary
    LONN   CH0013841017

LONZA GROUP AG

(LONN)
  Report
Delayed Swiss Exchange  -  11:31 2022-09-27 am EDT
445.00 CHF   +1.09%
08:43aAlphaValue/Baader Europe Lowers Price Target on Lonza, Upgrades Recommendation to Buy From Add
MT
09/14Lonza Boosts Swiss Site's Capacity to Produce Antibody-drug Conjugate Payloads
MT
09/12Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
EQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Lonza Confident on 2022 Goals as 1st Half Sales Book Healthy Rise

07/22/2022 | 01:36am EDT

By Joshua Kirby


Lonza Group AG on Friday backed its financial outlook for this year as sales and earnings rose strongly in the first half of 2022 thanks to good consumer demand.

Sales totalled 2.98 billion Swiss francs ($3.08 billion) in the six months, rising 17% from CHF2.54 billion in the same period last year, the Swiss life-sciences company said. Core earnings before interest, taxes, depreciation and amortization meanwhile rose 16.5% to CHF987 million, with a slight contraction in the margin to 33.1%.

Good demand in divisions including biologics and the cell & gene business helped drive sales growth in the half-year, Lonza said.

Looking ahead, Lonza said it expects to meet its full-year outlook of sales growth in the low-to-mid teens and an improvement in the core Ebitda margin, in line with mid-term guidance.

The biologics division will be boosted ahead by investment in a new commercial fill-and-finish facility in the municipality of Stein, as previously announced, said Chief Executive Pierre-Alain Ruffieux.

"This will help us to meet customer demand for an integrated offering and deliver long-term value to our business," he said.


Write to Joshua Kirby at joshua.kirby@wsj.com; @joshualeokirby


(END) Dow Jones Newswires

07-22-22 0135ET

Stocks mentioned in the article
ChangeLast1st jan.
LONZA GROUP AG 1.09% 445 Delayed Quote.-42.20%
SWISS LIFE HOLDING AG -1.06% 438.6 Delayed Quote.-20.70%
All news about LONZA GROUP AG
08:43aAlphaValue/Baader Europe Lowers Price Target on Lonza, Upgrades Recommendation to Buy F..
MT
09/14Lonza Boosts Swiss Site's Capacity to Produce Antibody-drug Conjugate Payloads
MT
09/12Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division
EQ
09/12Lonza Appoints Daniel Palmacci as President of the Cell & Gene Division, Effective from..
CI
09/12LONZA GROUP AG : Changes in management and corporate officers
CO
09/06Lonza Signs Collaboration Deal With Touchlight
MT
09/06Lonza and Touchlight collaborate on end-to-end mRNA offering
EQ
09/06Lonza and Touchlight Collaborate on End-To-End mRNA Offering
CI
08/31Lonza Plans Pair Of High-rise Buildings In Switzerland
MT
08/04Merck KGaA profit gets boost from dollar, outweighing higher costs
RE
More news
Analyst Recommendations on LONZA GROUP AG
More recommendations
Financials
Sales 2022 6 214 M 6 273 M 6 273 M
Net income 2022 1 038 M 1 048 M 1 048 M
Net cash 2022 350 M 353 M 353 M
P/E ratio 2022 31,7x
Yield 2022 0,74%
Capitalization 33 014 M 33 329 M 33 329 M
EV / Sales 2022 5,26x
EV / Sales 2023 4,74x
Nbr of Employees 17 154
Free-Float 99,6%
Chart LONZA GROUP AG
Duration : Period :
Lonza Group AG Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends LONZA GROUP AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 19
Last Close Price 440,20 CHF
Average target price 718,38 CHF
Spread / Average Target 63,2%
EPS Revisions
Managers and Directors
Pierre-Alain Ruffieux Chief Executive Officer
Philippe Deecke Chief Financial Officer
Albert M. Baehny Chairman
Maria Soler Nunez Head-Group Operations
Barbara May Richmond Independent Director
Sector and Competitors
1st jan.Capi. (M$)
LONZA GROUP AG-42.20%32 942
MODERNA, INC.-52.87%46 823
IQVIA HOLDINGS INC.-34.05%34 705
SEAGEN INC.-12.50%24 949
ALNYLAM PHARMACEUTICALS, INC.18.40%23 692
CELLTRION, INC.-16.92%15 895